
## Wei Deng

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/149892/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	<scp>TET2</scp> regulates <scp>LncRNAâ€ANRIL</scp> expression and inhibits the growth of human gastric cancer cells. IUBMB Life, 2016, 68, 355-364.	3.4	51
2	SMURF1 facilitates estrogen receptor É' signaling in breast cancer cells. Journal of Experimental and Clinical Cancer Research, 2018, 37, 24.	8.6	42
3	LncRNA-ANRIL promotes gastric cancer progression by enhancing NF-kB signaling. Experimental Biology and Medicine, 2019, 244, 953-959.	2.4	32
4	Orai1, a Direct Target of microRNA-519, Promotes Progression of Colorectal Cancer via Akt/CSK3β Signaling Pathway. Digestive Diseases and Sciences, 2016, 61, 1553-1560.	2.3	25
5	Camrelizumab combined with apatinib and S-1 as second-line treatment for patients with advanced gastric or gastroesophageal junction adenocarcinoma: a phase 2, single-arm, prospective study. Cancer Immunology, Immunotherapy, 2022, 71, 2597-2608.	4.2	25
6	Coffee consumption and the risk of incident gastric cancer—A meta-analysis of prospective cohort studies. Nutrition and Cancer, 2016, 68, 40-47.	2.0	19
7	Real-world outcomes of regorafenib combined with immune checkpoint inhibitors in patients with advanced or metastatic microsatellite stable colorectal cancer: A multicenter study. Cancer Immunology, Immunotherapy, 2022, 71, 1443-1451.	4.2	13
8	The Profile of Serum microRNAs Predicts Prognosis for Resected Gastric Cancer Patients Receiving Platinum-Based Chemotherapy. Digestive Diseases and Sciences, 2017, 62, 1223-1234.	2.3	12
9	Development and validation of a nomogram for further decision of radical surgery in pT1 colorectal cancer after local resection. International Journal of Colorectal Disease, 2021, 36, 1499-1506.	2.2	9
10	Inflammation-related indicators to distinguish between gastric stromal tumors and leiomyomas: A retrospective study. World Journal of Clinical Cases, 2022, 10, 458-468.	0.8	4
11	Apatinib plus S-1 for previously treated, advanced gastric or gastro-oesophageal junction adenocarcinoma: a phase 2, single-arm, prospective study. Journal of Gastrointestinal Oncology, 2021, 12, 2035-2044.	1.4	3
12	Development and Analytical Validation of a Targeted Next-Generation Sequencing Panel to Detect Actionable Mutations for Targeted Therapy. OncoTargets and Therapy, 2021, Volume 14, 2423-2431.	2.0	2
13	Nab-paclitaxel plus sintilimab as second-line therapy for advanced or metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJA): Preliminary results from an open-label, single-arm, phase 2 study Journal of Clinical Oncology, 2022, 40, 293-293.	1.6	2